Table 1 Cohort demographics and mean sex hormone levels
From: Plasma proteome adaptations during feminizing gender-affirming hormone therapy
CPA | SPIRO | |||
|---|---|---|---|---|
Baseline | 6-month GAHT | Baseline | 6-month GAHT | |
Sample size | 20 | 20 | 20 | 20 |
Mean ± s.e.m. (age range, IQR) | 25.4 ± 1.1 (18–36, 6.0) | 25.9 ± 1.1 (19–36, 7.0) | 26.1 ± 1.9 (20–58, 6.0) | 26.5 ± 1.8 (21–58, 6.25) |
Mean BMI kg m−2 (±s.e.m.) | 26.7 ± 1.5 | 27.1 ± 1.4 | 27.1 ± 1.7 | 28.2 ± 1.9 |
Mean sex hormone levels (±s.e.m.) | ||||
Estradiol (pmol l−1) | 154.8 ± 19.8 | 574.7 ± 80.3 | 246.2 ± 52.5 | 367.5 ± 45.6 |
Total testosterone (nmol l−1) | 18.1 ± 1.8 | 0.8 ± 0.1 | 17.4 ± 1.8 | 4.9 ± 1.3 |
PRL (mIU l−1) | 247.9 ± 17.1 | 662.3 ± 47.7 | 223.5 ± 15.3 | 277.0 ± 29.2 |
